糖尿病药物发展简史。
A Brief History of the Development of Diabetes Medications.
作者信息
White John R
出版信息
Diabetes Spectr. 2014 May;27(2):82-6. doi: 10.2337/diaspect.27.2.82.
Abstract
This article provides an overview of the development of insulins, oral agents, and noninsulin injectable agents used in the management of hyperglycemia in patients with diabetes. It also briefly reviews the pharmacological impact and salient side effects of these medications.
摘要
本文概述了用于治疗糖尿病患者高血糖的胰岛素、口服药物和非胰岛素注射药物的发展情况。还简要回顾了这些药物的药理作用和主要副作用。
相似文献
1
A Brief History of the Development of Diabetes Medications.
Diabetes Spectr. 2014 May;27(2):82-6. doi: 10.2337/diaspect.27.2.82.
2
Insulins and oral hypoglycemic medications.
Pediatr Endocrinol Rev. 2004 Nov;2 Suppl 1:153-62.
3
Pharmacotherapy for hyperglycemia in pregnancy - The new insulins.
Diabetes Res Clin Pract. 2018 Nov;145:59-66. doi: 10.1016/j.diabres.2018.04.035. Epub 2018 May 3.
4
Does treatment of noninsulin-dependent diabetes mellitus reduce the risk of coronary heart disease?
Curr Opin Lipidol. 1996 Aug;7(4):227-33. doi: 10.1097/00041433-199608000-00009.
5
Pharmacologic treatment of type 2 diabetes: injectable medications.
Ann Pharmacother. 2015 Jun;49(6):700-14. doi: 10.1177/1060028015573010. Epub 2015 Mar 23.
6
Insulin and oral agents for managing cystic fibrosis-related diabetes.
Cochrane Database Syst Rev. 2013 Jul 26(7):CD004730. doi: 10.1002/14651858.CD004730.pub3.
7
Pharmacologic treatment of type 2 diabetes: oral medications.
Ann Pharmacother. 2015 May;49(5):540-56. doi: 10.1177/1060028014558289. Epub 2015 Feb 9.
8
Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Curr Med Res Opin. 2010 Jan;26(1):231-8. doi: 10.1185/03007990903421994.
9
Use of Norplant in women with or at-risk for noninsulin-dependent diabetes.
J Nurse Midwifery. 1996 Jul-Aug;41(4):285-96. doi: 10.1016/0091-2182(96)00031-6.
10
Postoperative management of the diabetic patient.
Med Clin North Am. 2001 Sep;85(5):1213-28. doi: 10.1016/s0025-7125(05)70373-4.
引用本文的文献
1
Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends.
Curr Ther Res Clin Exp. 2025 Jul 23;103:100809. doi: 10.1016/j.curtheres.2025.100809. eCollection 2025.
2
2-Hydroxyisobutyric acid targeted binding to MT-ND3 boosts mitochondrial respiratory chain homeostasis in hippocampus to rescue diabetic cognitive impairment.
Redox Biol. 2025 Feb;79:103446. doi: 10.1016/j.redox.2024.103446. Epub 2024 Nov 28.
3
Trends in anti-diabetic medication use, severe hyperglycaemia and severe hypoglycaemia among American Indian and Alaska Native Peoples, 2009-2013.
Diabetes Obes Metab. 2025 Jan;27(1):328-337. doi: 10.1111/dom.16021. Epub 2024 Oct 21.
4
Evaluation of Interprofessional Delivery of Diabetes Medication Management Training Among Family Medicine Residents.
J Prim Care Community Health. 2024 Jan-Dec;15:21501319241276801. doi: 10.1177/21501319241276801.
5
Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review.
Diabetes Ther. 2024 Aug;15(8):1687-1716. doi: 10.1007/s13300-024-01612-8. Epub 2024 Jun 27.
6
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management.
Pharmacoeconomics. 2024 Sep;42(9):1017-1028. doi: 10.1007/s40273-024-01398-4. Epub 2024 Jun 26.
7
Trends in diabetes prevalence, awareness, treatment, and control in French-speaking Switzerland.
Sci Rep. 2024 Feb 28;14(1):4839. doi: 10.1038/s41598-024-54856-6.
8
Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV.
Drug Des Devel Ther. 2023 Nov 23;17:3473-3491. doi: 10.2147/DDDT.S426870. eCollection 2023.
9
Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes.
J Patient Rep Outcomes. 2023 Sep 6;7(1):89. doi: 10.1186/s41687-023-00614-7.
10
Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain.
J Clin Med. 2023 Aug 10;12(16):5218. doi: 10.3390/jcm12165218.
本文引用的文献
1
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
Diabetes Obes Metab. 2014 May;16(5):457-66. doi: 10.1111/dom.12244. Epub 2013 Dec 29.
2
History of current non-insulin medications for diabetes mellitus.
J Community Hosp Intern Med Perspect. 2012 Oct 15;2(3). doi: 10.3402/jchimp.v2i3.19081. Print 2012.
3
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19.
4
The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
Diabetes Metab Res Rev. 2011 Sep;27(6):528-42. doi: 10.1002/dmrr.1202.
5
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078.
6
Thiazolidinediones: the case for early use.
Diabetes Care. 2006 Jan;29(1):154-7. doi: 10.2337/diacare.29.1.154.
7
Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome).
Diabetes Care. 1981 May-Jun;4(3):360-5. doi: 10.2337/diacare.4.3.360.
8
Sulfonylureas: background and development of the field.
Diabetes Care. 1984 May-Jun;7 Suppl 1:3-7.
9
Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.
Diabetes Care. 1992 Feb;15(2):270-6. doi: 10.2337/diacare.15.2.270.
10
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
N Engl J Med. 1992 May 14;326(20):1316-22. doi: 10.1056/NEJM199205143262003.
Zotero 插件